| __timestamp | CRISPR Therapeutics AG | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 18516000 |
| Thursday, January 1, 2015 | 12573000 | 34140000 |
| Friday, January 1, 2016 | 42238000 | 51872000 |
| Sunday, January 1, 2017 | 69800000 | 71772000 |
| Monday, January 1, 2018 | 113773000 | 97501000 |
| Tuesday, January 1, 2019 | 179362000 | 118590000 |
| Wednesday, January 1, 2020 | 266946000 | 169802000 |
| Friday, January 1, 2021 | 438633000 | 192507000 |
| Saturday, January 1, 2022 | 461645000 | 199563000 |
| Sunday, January 1, 2023 | 387332000 | 253598000 |
| Monday, January 1, 2024 | 320653000 |
In pursuit of knowledge
In the dynamic world of biotechnology, innovation is the lifeblood that propels companies forward. CRISPR Therapeutics AG and Xencor, Inc. are two such pioneers, each with a unique approach to research and development (R&D). Over the past decade, CRISPR Therapeutics has consistently outpaced Xencor in R&D spending, with a staggering 60% more investment on average. This trend is evident from 2014 to 2023, where CRISPR's R&D expenses surged from a modest $1.5 million to nearly $462 million in 2022, before slightly dipping in 2023. Meanwhile, Xencor's investment grew steadily, peaking at approximately $254 million in 2023. This financial commitment underscores CRISPR's aggressive pursuit of cutting-edge gene-editing technologies, while Xencor focuses on antibody and protein engineering. As these companies continue to innovate, their R&D strategies will be crucial in shaping the future of biotechnology.
Research and Development: Comparing Key Metrics for Bristol-Myers Squibb Company and Xencor, Inc.
R&D Insights: How GSK plc and Xencor, Inc. Allocate Funds
argenx SE or CRISPR Therapeutics AG: Who Invests More in Innovation?
Insmed Incorporated vs Xencor, Inc.: Strategic Focus on R&D Spending
Ascendis Pharma A/S vs CRISPR Therapeutics AG: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Ionis Pharmaceuticals, Inc. and CRISPR Therapeutics AG
Who Prioritizes Innovation? R&D Spending Compared for Alkermes plc and CRISPR Therapeutics AG
Research and Development: Comparing Key Metrics for ADMA Biologics, Inc. and Xencor, Inc.
CRISPR Therapeutics AG vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Veracyte, Inc. vs Xencor, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: ACADIA Pharmaceuticals Inc. vs Xencor, Inc.
R&D Spending Showdown: Protagonist Therapeutics, Inc. vs Xencor, Inc.